AstraZeneca will invest $50 billion in the US by 2030, led by a massive drug manufacturing facility in Virginia, amid tariff threats from President Trump. The plan includes new R&D and production sites across key states, aiming to support next-gen therapies and US job growth. Stocktwits sentiment turned bullish after strong lung cancer trial results boosted optimism.